Thane Wettig - 06 Mar 2026 Form 4 Insider Report for KYNTRA BIO, INC. (KYNB)

Role
CEO, Director
Signature
/s/ John Alden, Attorney-in-Fact
Issuer symbol
KYNB
Transactions as of
06 Mar 2026
Net transactions value
$0
Form type
4
Filing time
10 Mar 2026, 17:41:32 UTC
Previous filing
05 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Wettig Thane CEO, Director C/O KYNTRA BIO, INC., 350 BAY STREET, SUITE 100, #6009, SAN FRANCISCO /s/ John Alden, Attorney-in-Fact 10 Mar 2026 0001815638

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYNB Common Stock Tax liability -277 -1.1% $6.84* 24,403 06 Mar 2026 Direct F1
holding KYNB Common Stock 40 06 Mar 2026 By spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units.